Trial Profile
Exploring and Subtyping the Pathophysiology of Neurodegeneration in Late-life Depression: Implications for Treatment and Prognosis in the Future
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2022
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary) ; Fluorine 18 THK 5351 (Primary)
- Indications Major depressive disorder
- Focus Diagnostic use
- 25 Jan 2022 Status changed from recruiting to completed.
- 04 Aug 2021 Status changed from active, no longer recruiting to recruiting.
- 17 Jul 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.